EXPLORE!

A Cancer Drug Reduces the Risk of Covid-19 Death Significantly

  525 Views

eMediNexus    10 July 2022

Sabizabulin, a drug developed by Veru Pharmaceuticals, has shown favorable results in an interim analysis of a phase 3 placebo-controlled trial. Treatment with this oral anti-cancer drug has reduced the risk of death by more than 55% in hospitalized patients with COVID-19. Dr. Mitchell Steiner, MD, Veru Pharmaceuticals stated that the drug showed a consistent and significant reduction in deaths across all patient subgroups, regardless of the standard of care, baseline WHO scores, co-morbidities, vaccination status, geography, etc.

The analysis published in "NEJM Evidence" showed that the mortality rate was 20.2% in the treatment group in comparison to 45.1% in the placebo group. The study included 150 hospitalized adults with moderate to severe COVID-19 symptoms, who were randomly allocated to receive a daily dose of sabizabulin (9 mg) or a placebo drug for 21 days.

The study reported that sabizabulin led to a significant reduction in ICU days, mechanical ventilation, and adverse drug reactions by 43%, 49%, and 61.5%, respectively. Meanwhile, in the placebo group, 78.3% of adverse drug reactions were reported.

(Source: https://www.medscape.com/viewarticle/976786 )

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.